Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens by Kuczkowska, Katarzyna et al.
Immunogenic Properties of Lactobacillus
plantarum Producing Surface-Displayed
Mycobacterium tuberculosis Antigens
Katarzyna Kuczkowska,a Charlotte R. Kleiveland,a,b Rajna Minic,c Lars F. Moen,a
Lise Øverland,a Rannei Tjåland,a Harald Carlsen,a Tor Lea,a Geir Mathiesen,a
Vincent G. H. Eijsinka
Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences (NMBU), Ås,
Norwaya; Smerud Medical Research International AS, Oslo, Norwayb; Department of Research and
Development, Institute of Virology, Vaccines and Sera Torlak, Belgrade, Serbiac
ABSTRACT Tuberculosis (TB) remains among the most deadly diseases in the world.
The only available vaccine against tuberculosis is the bacille Calmette-Guérin (BCG)
vaccine, which does not ensure full protection in adults. There is a global urgency
for the development of an effective vaccine for preventing disease transmission, and
it requires novel approaches. We are exploring the use of lactic acid bacteria (LAB)
as a vector for antigen delivery to mucosal sites. Here, we demonstrate the success-
ful expression and surface display of a Mycobacterium tuberculosis fusion antigen
(comprising Ag85B and ESAT-6, referred to as AgE6) on Lactobacillus plantarum. The
AgE6 fusion antigen was targeted to the bacterial surface using two different an-
chors, a lipoprotein anchor directing the protein to the cell membrane and a cova-
lent cell wall anchor. AgE6-producing L. plantarum strains using each of the two an-
chors induced antigen-specific proliferative responses in lymphocytes purified from
TB-positive donors. Similarly, both strains induced immune responses in mice after
nasal or oral immunization. The impact of the anchoring strategies was reflected in
dissimilarities in the immune responses generated by the two L. plantarum strains in
vivo. The present study comprises an initial step toward the development of L. plan-
tarum as a vector for M. tuberculosis antigen delivery.
IMPORTANCE This work presents the development of Lactobacillus plantarum as a
candidate mucosal vaccine against tuberculosis. Tuberculosis remains one of the top
infectious diseases worldwide, and the only available vaccine, bacille Calmette-
Guérin (BCG), fails to protect adults and adolescents. Direct antigen delivery to mu-
cosal sites is a promising strategy in tuberculosis vaccine development, and lactic
acid bacteria potentially provide easy, safe, and low-cost delivery vehicles for muco-
sal immunization. We have engineered L. plantarum strains to produce a Mycobacte-
rium tuberculosis fusion antigen and to anchor this antigen to the bacterial cell wall
or to the cell membrane. The recombinant strains elicited proliferative antigen-
specific T-cell responses in white blood cells from tuberculosis-positive humans and
induced specific immune responses after nasal and oral administrations in mice.
KEYWORDS Lactobacillus plantarum, LAB, tuberculosis, Mycobacterium tuberculosis,
mucosal vaccine, bacteriology, immunology, lactic acid bacteria
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and remainsamong the most deadly human pathogens (1). About one-third of the world’s
population is infected with M. tuberculosis, and in 2014, the bacterium killed about 1.5
million people, of which 1.1 million were HIV negative (2). The current vaccine against
TB is an attenuated form of Mycobacterium bovis known as bacille Calmette-Guérin
(BCG). The BCG vaccine prevents TB in infants with high efficacy, but it fails to protect
Received 6 October 2016 Accepted 27
October 2016
Accepted manuscript posted online 4
November 2016
Citation Kuczkowska K, Kleiveland CR, Minic R,
Moen LF, Øverland L, Tjåland R, Carlsen H, Lea
T, Mathiesen G, Eijsink VGH. 2017.
Immunogenic properties of Lactobacillus
plantarum producing surface-displayed
Mycobacterium tuberculosis antigens. Appl
Environ Microbiol 83:e02782-16. https://
doi.org/10.1128/AEM.02782-16.
Editor Harold L. Drake, University of Bayreuth
Copyright © 2016 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Katarzyna
Kuczkowska, katarzyna.kuczkowska@nmbu.no,
or Geir Mathiesen, geir.mathiesen@nmbu.no.
BIOTECHNOLOGY
crossm
January 2017 Volume 83 Issue 2 e02782-16 aem.asm.org 1Applied and Environmental Microbiology
 on F








against pulmonary disease in adolescents and adults (3, 4). In addition, the current BCG
vaccine is not recommended for use in HIV-infected individuals, especially infants (5, 6).
Therefore, the development of an effective vaccine for preventing disease transmission
is urgent and remains a global priority. Currently, 15 vaccine candidates undergoing
clinical trials are targeted to adolescents and adults rather than to children (2).
The most commonly used M. tuberculosis antigens are proteins produced by actively
growing and metabolizing bacteria, such as proteins from the antigen 85 family
(Ag85A, Ag85B, and Ag85C), which are considered virulence factors with high immu-
nogenicity (7–9). Proteins belonging to the ESAT-6 family also possess strong antigenic
properties and are known to be the main targets for T cells in the early infection phase
(10, 11). Immunity to TB involves numerous different mechanisms, cell subsets, and
cytokines (9, 12, 13). It is well established that the induction of a Th1 response, with the
essential role of CD4 T cells and contributions of interferon (IFN)- and tumor necrosis
factor (TNF)-, is a critically important element of the protective response against TB
(12–15).
Bacteria are interesting potential vectors for the delivery of vaccines, particularly
mucosal vaccines (16–20). Bacteria are simple to culture by fermentation, and access to
a large genetic engineering toolbox allows for control of antigen expression and
fine-tuning of antigenic properties. The approach of using microorganisms as a delivery
vector for antigens has already been applied to developing a mucosal vaccine against
TB. Live recombinant attenuated Salmonella strains secreting an M. tuberculosis fusion
antigen induce Th1 responses when used as oral vaccines (21). Furthermore, Salmonella
enterica serovar Typhimurium engineered to deliver a DNA vaccine against TB elicits a
specific immune response in mice and provides protection to the lungs and spleen after
intranasal immunization (22). Recombinant variants of the commensal bacterium Strep-
tococcus mitis expressing M. tuberculosis Ag85B have been shown to colonize gnoto-
biotic piglets and induce production of specific IgG and IgA antibodies after oral
administration (23).
Nonpathogenic Gram-positive food-grade bacteria, particularly lactic acid bacteria
(LAB), have been widely exploited as an alternative to attenuated pathogens. Due to
their safe status and well-developed genetic engineering methods, LAB have a great
potential as delivery vectors for antigens. Results from studies over the past 25 years
show progress in the development of LAB as mucosal vaccine vectors (19, 24–28).
Several lactic acid bacteria belonging to the Lactobacillus genus are known to modulate
the immune system by interacting with dendritic cells (DCs) and to skew a subsequent
T-cell response toward Th1 polarization (29). The immunomodulatory properties of
lactobacilli vary between strains (30, 31), and Lactobacillus plantarum was described as
a potential immunological adjuvant in the late 1970s (32). Currently, many studies
support the view that L. plantarum enhances the mucosal immune response without
negatively influencing immune homeostasis (33). These traits increase the attractive-
ness of L. plantarum as a candidate vehicle for antigen delivery.
In this study, we exploited L. plantarum for production of M. tuberculosis antigens,
with the ultimate aim of developing a candidate mucosal vaccine against tuberculosis.
We developed bacteria that display a fusion protein comprising the antigens Ag85B
and ESAT-6 (referred to as AgE6) on the surface using one of two different anchoring
domains: an N-terminal lipoprotein anchor or a C-terminal cell wall anchor. Using
peripheral blood mononuclear cells (PBMCs) isolated from TB-positive blood donors,
we show that AgE6-producing L. plantarum strains induced antigen-specific memory
T-cell responses in vitro. Subsequently, we investigated the immunogenic potential of
our strains in vivo using a mouse model.
RESULTS
Construction of L. plantarum strains for display of the AgE6 fusion antigen. Two
different anchors were used for surface display of the AgE6 hybrid antigen, and a
schematic overview of the generated expression vectors is provided in Fig. 1. The
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expression plasmids were constructed to link the AgE6 protein to the cell surface via a
C-terminal cell wall anchor (Fig. 1A) or an N-terminal lipoprotein anchor (Fig. 1B).
For C-terminal anchoring, we selected a cell wall anchor (cwa2) derived from
Lp_2578 (34) that contains an LPXTG domain, which is expected to lead to covalent
binding to the peptidoglycan. In addition, a peptide with known affinity for dendritic
cells (DCs) (35, 36) was fused to the N-terminal end of the fusion protein. After
C-terminal anchoring to the peptidoglycan, the N-terminal DC-binding peptide was
expected to protrude from the bacterial cell surface (Fig. 1A).
In the second construct, we used a lipoprotein anchor derived from Lp_1261, which
is expected to lead to covalent binding of the N terminus to the cell membrane (37).
The N-terminal end of the AgE6 protein was fused to the lipoprotein anchor, whereas
the DC-binding peptide was fused to the C-terminal end of the antigen such that it was
expected to protrude from the bacterial cell (Fig. 1B). As a negative control, we used an
L. plantarum strain harboring the empty vector pEv (37).
Production and surface display of AgE6. To induce the expression of anchor-fused
AgE6 protein, we added a peptide pheromone to growing recombinant L. plantarum
strains (38). We then analyzed protein production in crude cell-free protein extracts by
Western blotting using an anti-ESAT-6 antibody (Fig. 2A). The protein extracts from L.
plantarum bacteria harboring pLp_1261AgE6-DC showed a band of the expected size
(48.4 kDa) and two additional bands of slightly smaller sizes that most likely were
breakdown products. The protein extracts from the strain harboring pLp_3050DC-
AgEcwa2 showed only one distinct band. The molecular mass of this protein was higher
than the expected 61.2-kDa size. Such a shift is commonly observed when using the
cwa2 anchor (34, 39, 40) and likely results from covalent binding to the peptidoglycan
layer. No bands were observed in the protein extracts from the negative-control strain.
Additionally, we evaluated the amount of surface-coupled AgE6 relative to the total
amount of AgE6 produced by the bacterial cells (Fig. 2B) and we compared production
by the two AgE6-displaying L. plantarum strains. Intact bacterial cells were used to
determine surface-located AgE6, whereas crude protein extracts were used to detect
total AgE6. The dot-plot analysis revealed stronger signals for Lp_1261AgE6-DC in both
the surface-located and total protein fractions (Fig. 2B). The data show that Lp_
1261AgE6-DC produced more antigen than did Lp_DC-AgE6cwa2 and that a larger
fraction of the antigen was targeted to the cell surface.
After labeling of live bacteria with an anti-ESAT-6 antibody, surface display of the
AgE6 antigen was investigated by flow cytometry (Fig. 3A) and fluorescence micro-
FIG 1 Expression cassettes for production of surface-displayed AgE6. All parts of the cassette are easily exchange-
able using the indicated restriction sites. (A) C-terminal anchoring to the cell wall was accomplished by fusing the
N terminus of AgE6 to the signal peptide from Lp_3050 (SP3050) and the C terminus to a cell wall anchor from
Lp_2578 (cwa2, which comprises the C-terminal 194 residues of Lp_2578) (34). (B) N-terminal anchoring via a
lipoprotein anchor was achieved by fusing the N terminus of AgE6 to residue 75 of Lp_1261 (this part of Lp_1261
includes a 23-residue signal peptide, SP1261). The position of the 12-residue DC-binding peptide (DC) is also
indicated. PsppA indicates the pheromone-inducible promoter that drives gene expression.
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scopy (Fig. 3B). Figure 3A shows a substantial increase in fluorescence intensity for the
antigen-producing bacteria compared to that in the negative control. The flow cytom-
etry data were confirmed by immunofluorescence microscopy, which revealed green
cells for only the strains expected to have AgE6 at the surface (Fig. 3B).
Antigen-specific lymphocyte proliferative responses of human PBMCs. To in-
vestigate the ability of AgE6-producing Lactobacillus bacteria to induce an antigen-
specific immune response in vitro, we stimulated PBMCs purified from TB-positive
donors with the recombinant bacteria and measured T-cell responses (Fig. 4). The
proliferation of lymphocytes induced by AgE6-producing Lactobacillus bacteria was
higher than in the negative control, Lp_Ev (Fig. 4), and the two AgE6-expressing strains
induced similar proliferative responses. We also observed proliferation in response to
BCG and purified protein derivative (PPD), confirming that the cells from TB-positive
donors responded to M. tuberculosis antigens.
Antigen-specific IFN- production by splenocytes from immunized mice. Mice
were immunized by either intranasal or oral administration of the L. plantarum strains
producing surface-displayed AgE6, Lp_1261AgE6-DC and Lp_DC-AgE6cwa2. Mice that
were administered PBS and Lp_Ev were used as negative controls. A BCG-immunized
group was also included.
A Th1 response, particularly the antigen-specific production of IFN- by memory cells,
is thought to be crucial in protecting against M. tuberculosis infection (15). Therefore, we
investigated the frequency of IFN--secreting splenocytes from immunized mice by
enzyme-linked immunosorbent spot (ELISPOT) assays after in vitro restimulation with
purified recombinant AgE6 (rAgE6) (Fig. 5). Oral vaccination with Lp_1261AgE6-DC
resulted in a significantly higher frequency of AgE6-specific IFN--secreting spleen cells
than that seen with PBS and Lp_Ev, whereas oral vaccination with Lp_DC-AgE6cwa2 did
not increase the number of IFN- secretors compared with that in the negative-control
groups (Fig. 5A). Intranasal immunization increased the numbers of AgE6-specific
cytokine-producing splenocytes for both AgE6-producing strains, but the differences
relative to the negative control were not statistically significant (Fig. 5B). Interestingly,
FIG 2 Detection of AgE6 produced by L. plantarum strains. (A) The anchor-fused AgE6 in strains
Lp_1261AgE6-DC (predicted size, 48 kDa) and Lp_DC-AgE6cwa2 (predicted size, 61 kDa) was analyzed by
Western blotting. A strain harboring the pEv plasmid (empty vector) (37) was used as a negative control.
(B) Comparison of AgE6 fractions in total protein extracts (E) and surface-located AgE6 detected on intact
bacterial cells (S) for both antigen-producing strains. In both analyses, bacterial cultures were harvested
3 h after induction and the hybrid AgE6 was detected using a monoclonal mouse anti-ESAT-6 antibody
and polyclonal rabbit anti-mouse HRP-conjugated IgG. The data presented are from one representative
experiment. Each experiment was performed at least three times and gave similar results.
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splenocytes from mice immunized with BCG did not show elevated production of IFN-
after stimulation with rAgE6 (Fig. 5A and B).
Antigen-specific PBMC proliferative responses from intranasally immunized
mice. Antigen-mediated PBMC responses from intranasally immunized mice were
measured by the thymidine incorporation assay. Due to low yields of PMBCs isolated
from individual mice, freshly isolated cells within each group were pooled (4 mice per
group). The results (Fig. 6) showed that the rAgE6-induced proliferation of PBMCs from
Lp_1261AgE6-DC-vaccinated mice was significantly higher than for all other groups.
Notably, we did not observe increased proliferation for the Lp_DC-AgE6cwa2 and BCG
groups (Fig. 6).
FIG 3 Analysis of the surface localization of AgE6 by flow cytometry (A) and indirect immunofluorescence
microscopy (B). L. plantarum cells harboring plasmids designed for N- or C-terminal anchoring of AgE6 were probed
with a mouse anti-ESAT-6 monoclonal antibody and subsequently with an FITC-conjugated rabbit anti-mouse IgG
antibody. L. plantarum harboring the pEv plasmid, lacking the antigen gene fragment, was used as a negative
control (black line in both histograms in panel A). Panel B shows bright field, fluorescence, and overlay images. The
data presented are from one representative experiment. Each experiment was performed at least three times and
gave similar results.
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We were unable to carry out a similar experiment for orally immunized mice,
because the amount of PBMCs was not sufficient to set up the proliferation assay.
Antigen-specific IgA secretion in mucosal sites of orally immunized mice.
Secretory IgAs play a crucial role in immune defense at mucosal surfaces. To investigate
the mucosal immune response induced by oral immunization with AgE6-displaying L.
plantarum, we determined the levels of antigen-specific IgA in feces using an enzyme-
linked immunosorbent assay (ELISA). Figure 7A shows increased levels of IgA in fecal
samples from mice immunized with Lp_DC-AgE6cwa2, Lp_1261AgE6-DC, or BCG com-
pared with the levels in the control groups. Additionally, we measured total IgA in fecal
samples from groups immunized with L. plantarum-based vaccines (Lp_Ev, Lp_DC-
AgE6cwa2, and Lp_1261AgE6-DC), enabling normalization of AgE6-specific IgA levels to
total IgA levels. No differences in total IgA levels were detected (data not shown);
consequently, the normalized data (Fig. 7B) show trends similar to those of the
FIG 5 Frequency of IFN--secreting splenocytes isolated from mice immunized via the oral (A) or the nasal (B)
route. Splenocytes were purified and incubated with the purified AgE6 protein for 36 to 48 h. IFN--secreting cells
were enumerated by ELISPOT. Results are presented as spot-forming units (SFU) per number of stimulated
splenocytes. Each point represents one mouse and an average of technical duplicates; the overall results per group
are presented as means  SEMs (n  4). *, P 0.05; **, P  0.01.
FIG 4 Proliferation of PBMCs isolated from TB-positive blood donors presented for grouped (A) and
individual (B) donors. PBMCs were purified from individual donors and stimulated with Lp_Ev,
Lp_1261AgE-DC, Lp_DC-AgEcwa2, BCG, or PPD for 8 to 10 days. Lymphocyte proliferation was measured
using the thymidine incorporation assay. Each point represents an average of technical triplicates for one
donor and is presented as a stimulation index (fold change relative to unstimulated cells). The results per
group presented in panel A are the means  SEMs (n  9 for L. plantarum and BCG stimulation; n  6
for PPD stimulation). *, P 0.05; **, P 0.01. In panel B, each symbol represents one blood donor; the
lines illustrate how individual donors responded to the various stimuli.
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nonnormalized data, i.e., a higher level of production of AgE6-specific IgA in mice
administered the AgE6-displaying strains.
DISCUSSION
In the last 25 years, LAB have been widely used for the production of heterologous
proteins, including antigens from pathogenic bacteria. LAB are promising candidates
for vaccine delivery, since they interact with mucosal surfaces and may have adjuvant
properties. In this study, we engineered L. plantarum bacteria for surface display of
antigens derived from M. tuberculosis to investigate the potential of surface-located
TB-antigens for inducing immune responses in mice. The model LAB, Lactococcus lactis,
has already been exploited as a potential delivery vector for a mucosal DNA vaccine
against TB and one of the engineered Lactococcus strains was shown to induce a
Th1-cell immune response in mice (41). In our work, we selected L. plantarum due to the
stronger immunomodulatory properties of this species (42), and we focused on protein
rather than on gene delivery.
Previous studies have shown that surface display of heterologous proteins on
Lactobacillus using various anchoring methods leads to varying levels of functionality in
FIG 7 Antigen-specific IgA antibodies detected after oral immunization by ELISA. Fecal samples were collected
from mice on the termination day and pooled within each group (4 mice per group). (A) Detection of antigen-
specific IgA in the different groups using recombinant AgE6 protein. The results are presented as means of at least
three independent measurements of OD405  SEMs. *, P 0.05. (B) Values for groups immunized with Lp_Ev,
Lp_1261AgE-DC, or Lp_DC-AgEcwa2 after normalization by total IgA (based on the OD values). The results
represent the ratios of antigen-specific IgA versus total IgA and are presented as a mean of duplicates  SEMs.
FIG 6 Proliferation of PBMCs isolated from mice immunized via the intranasal route. PBMCs from
individual mice were purified and pooled within each group (4 mice per group); 1  105 PBMCs for each
group were incubated with rAgE6 for 7 days. PMBC proliferation was measured using the thymidine
incorporation assay. Results are presented as counts per minute (CPM). Bars represent means of triplicate
values  SEMs. ***, P 0.001.
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vitro and in vivo (37, 39, 40, 43). The N-terminal lipoprotein anchor used in this study has
previously been used for functional display of invasin from Yersinia pseudotuberculosis
(37) and a CCL3 chemokine (39), whereas the C-terminal cell wall anchor has been
exploited for functional display of cancer antigens (34, 44) and an anti-DEC-205
antibody (40).
Flow cytometry (Fig. 3A) and fluorescence microscopy (Fig. 3B) confirmed the
surface localization of AgE6 in both strains. The results from the human lymphocyte
proliferation assay demonstrate that the surface-located hybrid M. tuberculosis antigen
was recognized by memory T cells of TB-positive donors in vitro (Fig. 4). In this in vitro
test system, we did not observe significant differences between the two AgE6-
expressing strains.
For the evaluation of Lp_1261AgE6-DC and Lp_DC-AgE6cwa2 as potential TB vac-
cines in mice, we selected two administration routes, namely oral and nasal. M.
tuberculosis uses the mucosa of the respiratory tract for invasion, and targeting of
antigens to the respiratory tract via intranasal injection or inhalation is a commonly
explored strategy in TB vaccine development (45–47). On the other hand, when it
comes to L. plantarum, the oral route is of interest, because this food-grade bacterium
is a natural resident of the intestinal microflora (48, 49). Mucosal immunization is
potentially highly advantageous in vaccinology since the majority of pathogens enter
the body via mucosal surfaces and it has been established that mucosal vaccination
generates both mucosal and systemic immune protection (47, 50).
IFN- production by Th1 cells is central in controlling TB, because this proinflam-
matory cytokine activates macrophages, which are a target for M. tuberculosis infection
(51, 52). We observed a significantly increased AgE6-specific IFN- response in spleen
cells isolated from mice immunized orally with Lp_1261AgE6-DC (Fig. 5A), suggesting
a specific systemic reaction in response to the AgE6 delivered by this strain. It was
shown previously that oral vaccination with M. tuberculosis antigens leads to detectable
mucosal and systemic immune responses (53–55) and even induces protective immu-
nity in the lungs of mice and guinea pigs (54, 55). The lack of an increase in IFN-
production by AgE6-stimulated splenocytes from BCG-vaccinated mice may be due to
the fact that BCG does not contain ESAT-6 (56). In contrast to what was observed for
mice orally immunized with lipoprotein-anchored AgE6, the number of IFN--secreting
splenocytes did not increase in mice that had been orally immunized with Lp_DC-
AgE6cwa2. Importantly, antigens coupled with the cell wall anchor (cwa2) are located
on the most external part of the bacterial cells, whereas in the case of lipoprotein
anchoring (Lp_1261), the displayed proteins are likely to be more embedded in the cell
wall. This difference may cause the cell wall-anchored AgE6 protein to be more prone
to digestive activity in the gastrointestinal tract, which may reduce its efficacy in oral
immunization. It is also possible that the difference between the strains is due to, or
augmented by, different levels of surface-displayed antigens (Fig. 2B). Interestingly,
upon nasal administration, we observed an increased frequency of IFN--secreting
splenocytes for groups immunized with either of the two AgE6-producing L. plantarum
strains (Fig. 5B). However, in this case, due to the rather large variability among the
individual mice, we were not able to obtain statistical significance.
In vitro stimulation of PBMCs isolated from intranasally immunized animals showed
that cells from mice immunized with Lp_1261AgE6-DC proliferated to a significantly
higher degree than each of the other groups (Fig. 6). There is no obvious explanation
for our observation that the antigen-specific IFN- response generated in the spleen of
mice intranasally immunized with Lp_DC-AgE6cwa2 was not reflected in the PBMC
proliferation assay. However, such apparent inconsistencies are not unique, since
previous studies have found that T-cell proliferation does not necessarily correlate with
IFN- production by memory cells (57, 58).
IgA antibodies are a major component of humoral immunity at mucosal sites and
play a crucial role in neutralizing pathogens (59, 60). Recent studies in animal models
have found that antigen delivery by orally administered L. plantarum may elicit secre-
tion of specific IgA antibodies against antigens related to influenza (61), cancer (44),
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foot-and-mouth disease virus (FMDV) (62), and classical swine fever virus (63). In this
regard, we investigated whether orally administered AgE6-displaying L. plantarum
induced production of AgE6-specific IgA antibodies at intestinal mucosa. The results for
the Lp_1261AgE6-DC and Lp_DC-AgE6cwa2 groups indicated that both strains elicited
secretion of antigen-specific IgAs, but the elevation of the IgA levels was not statistically
significant relative to those of the negative controls. The secretion of specific IgA
antibodies was significantly increased in mice immunized with BCG relative to that in
the negative controls (Fig. 7), suggesting successful induction of a mucosal antibody
response to the Ag85B antigen in BCG.
To summarize, the results show that both AgE6-displaying L. plantarum strains elicit
specific immune responses after intranasal and oral administrations. Lp_1261AgE6-DC
seemed to be a stronger inducer of immunity regardless of the administration route.
One possible explanation may simply be that there was a higher level of production of
antigen (both total and surface located), meaning that higher doses of antigen were
used when applying this strain for immunization. Better control and improved produc-
tion of antigens in the bacterial cells might be one way to obtain stronger responses.
Nevertheless, the results represent an encouraging step in the development of L.
plantarum as a carrier for TB antigens. The system explored here provides noninvasive
mucosal immunization and benefits from the safe status and likely the natural immune-
modulating properties of L. plantarum. Notably, there are clear roads to further improve
the system, such as coexpression and coadministration of adjuvants, exploration of
other antigens, and coexpression of multiple antigens.
In conclusion, the present study shows that L. plantarum produces the hybrid
Ag85B-ESAT-6 antigen (AgE6) and displays it on the bacterial surface using two
different anchors. In vitro experiments demonstrate that blood cells from TB-positive
patients proliferate in response to AgE6 antigens produced by L. plantarum. In vivo
analyses show that both vaccine candidates induce antigen-specific immune responses
after oral or nasal immunization. This study suggests that L. plantarum may have
potential as a vector for delivering M. tuberculosis antigens to mucosal sites, which may
be a new approach in future TB vaccine development. Additional modifications and
improvements, including adjuvant strategies, are possible and should be studied to
improve this microbial delivery system.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains and plasmids used in this
study are listed in Table 1. Lactobacillus plantarum strains were cultured in MRS broth (Oxoid Ltd.,
Basingstoke, United Kingdom) at 37°C without shaking. Escherichia coli TOP10 cells (Invitrogen) were
grown in brain heart infusion (BHI) broth (Oxoid) at 37°C with shaking. Erythromycin was added to a final
concentration of 10 g/ml for L. plantarum. For E. coli, final concentrations of erythromycin and ampicillin
were 200 g/ml and 100 g/ml, respectively. Liquid medium was solidified by adding 1.5% (wt/vol) agar.
DNA manipulations and plasmid construction. The primers used in this study are listed in Table
2, and the basic outline of the constructed expression vectors is shown in Fig. 1. All plasmids used in this
study for expression in Lactobacillus spp. are derivatives of the modular pSIP400 vector series, con-
structed and developed for inducible gene expression, secretion, and surface anchoring of proteins (34,
64–67). Plasmids pLp_0373OFAcwa2 (34), pLp_1261Inv (37), and pLp_3050NucA (67) were used as
starting points. The Ag85B–ESAT-6 gene fragment was designed so that the predicted signal sequence
of Ag85B (68) was removed and the C-terminal end of the Ag85B antigen was fused to the ESAT-6
antigen. A three-amino-acid linker encoding Gly-Thr-Ala and containing a KpnI restriction site was
introduced between the two antigens for their easy exchange in the future. The Ag85B–ESAT-6 gene
fragment encoding the Ag85B–ESAT-6 fusion (AgE6) was optimized for expression in L. plantarum,
synthesized at GenScript (Piscataway, NJ), and cloned into a pUC57 plasmid, yielding pUC-AgE6. The
gene fragment encoding AgE6 was amplified from pUC-AgE6 using the AgMluR and AgSalIF primers. The
PCR fragment was directly cloned into the PCR-Blunt TOPO vector (Invitrogen), and the resulting plasmid
was digested by SalI and MluI. The resulting 1.2-kb AgE6-encoding fragment was cloned into SalI/MluI-
digested pLp_0373OFAcwa2 (34), yielding pLp_0373AgE6cwa2. To exchange the Lp_0373 signal peptide
with the Lp_3050 signal peptide, the pLp_0373AgE6cwa2 plasmid was digested with SalI and HindIII and
the 1.8-kb gene fragment encoding AgE6cwa2 was ligated into SalI/HindIII-digested pLp_3050NucA (67),
yielding pLp_3050AgE6cwa2. A gene fragment encoding a 12-residue-long DC-binding sequence
(FYPSYHSTPQRP) (35, 36) was fused to the 5= end of the antigen-encoding gene fragment by overlap
extension-PCR in three subsequent PCRs. In the first step, the DNA fragment was amplified from
pLp_3050AgE6cwa2 using primer pair P1-DCF/AgMluR. The PCR product was used as a template in the next
PCR with primers P2-DCF and AgMluR. Subsequently, the PCR product was used as a template in the next
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amplification reaction with primer pair P3-DCF/AgMluR. The final PCR fragment was subcloned into the
PCR-Blunt TOPO vector (Invitrogen), and the resulting plasmid was digested with SalI and MluI. The resulting
1.2-kb fragment encoding DC-AgE6 was cloned into SalI/MluI-digested pLp_3050AgE6cwa2, yielding the final
expression vector, pLp_3050DC-AgE6cwa2.
To construct the vector with a lipoprotein anchor, the sequence encoding AgE6 was amplified from
pUC-AgE6 using the pAgESAT-CytF and pAgESAT-CytR primers. The 1.2-kb PCR fragment was subcloned
into the PCR-Blunt TOPO vector, and the resulting plasmid was digested with NdeI and HindIII. The
fragment encoding AgE6 was cloned into NdeI/HindIII-digested pLp_3050NucA, yielding pSip_AgE6.
TABLE 1 Plasmids and strains used in this study
Strain or plasmid Descriptiona Reference/source
Plasmids
pUC-AgE6 Ampr, pUC57 vector with synthetic Ag85B–ESAT-6 gene GenScript
pBAD/HisB-EF Ampr, pBAD/HisB (Invitrogen) derivative, containing the gene encoding EfEndo18A 69
pBAD-AgE6 Ampr; pBAD/HisB-EF derivative, where the gene sequence encoding the EfEndo18A protein was
replaced by a fragment encoding the AgE6 fusion antigen
This study
pEV Eryr, control plasmid (“empty vector”) 37
pLp_1261Inv Eryr, pLp_2588AmyA (66) derivative, encoding a lipoprotein anchor sequence from Lp_1261
fused to an inv gene fragment
37
pLp_3050NucA Eryr, pSIP401 (64) derivative, encoding the signal peptide sequence from Lp_3050 fused to the
nucA gene
67
pSip_AgE6 Eryr, pLp_3050NucA derivative, where the gene sequence encoding the Lp_3050NucA protein
was replaced by the gene sequence encoding the AgE6 fusion antigen
This study
pLp_0373OFAcwa2 Eryr, pLp_0373Nuc derivative, encodes the signal peptide sequence from Lp_0373 fused to the
ofa gene and a subsequent cell wall anchor-encoding sequence (cwa2)
34
pLp_0373AgE6cwa2 Eryr, pLp_0373OFAcwa2 derivative, where the ofa gene fragment was replaced by a fragment
encoding the AgE6 fusion antigen
This study
pLp_1261AgE6 Eryr, pLp_1261Inv derivative, where the inv gene fragment was replaced by a fragment
encoding the AgE6 fusion antigen
This study
pLp_1261AgE6-DC Eryr, pLp_1261AgE6 derivative, encodes the AgE6 antigen with a DC-binding peptide fused to
its C terminus
This study
pLp_3050AgE6cwa2 Eryr, pLp_0373OFAcwa2 derivative, where the ofa gene was replaced by a gene encoding the
AgE6 fusion antigen and the Lp_0373 signal sequence was replaced by the Lp_3050 signal
sequence
This study
pLp_3050DC-AgE6cwa2 Eryr, pLp_3050Ag8E6cwa2 derivative, where a DC-binding peptide was inserted between the
Lp_3050 signal sequence and the N terminus of the AgE6 antigen
This study
Strains
L. plantarum WCFS1 Host strain 79
E. coli TOP10 Host strain Invitrogen
Lp_1261AgE6-DC L. plantarum WCFS1 harboring pLp_1261AgE6-DC, for surface display of the AgE6 fusion
antigen using an N-terminal covalent lipoprotein anchor
This study
Lp_DC-AgE6cwa2 L. plantarum WCFS1 carrying pLp_3050DC-AgE6cwa2, for surface display of the AgE6 fusion
antigen using a C-terminal covalent cell wall anchor (cwa2)
This study
Lp_Ev L. plantarum WCFS1 carrying pEv (empty vector), used as a negative-control strain 37
aEfEndo18A, Enterococcus faecalis endo--N-acetylglucosaminidase 18A.















aItalic font indicates restriction sites; bold font indicates parts of the DC-binding peptide; underlining
indicates 15-bp extensions that are complementary to the ends of the BglII/HindIII-digested pBAD vector
(such overlapping sequences are necessary when using in-fusion cloning).
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Subsequently, the pSip_AgE6 plasmid was digested with SalI and HindIII, and the fragment encoding
AgE6 was ligated to pLp_1261Inv (37) digested with the same enzymes, resulting in pLp_1261AgE6. The
gene fragment encoding Lp_1261AgE6 was then amplified using the SekF and DC-E6R primers and
pLp_1261AgE6 as the template, whereas a 36-bp DNA fragment encoding the DC-binding sequence was
amplified using the E6-DCF and Hind-DCR primers and pLp_DC-AgE6cwa2 as a template. The products
of these two PCRs, with 38-bp overlapping fragments, were fused in a subsequent overlap extension-PCR
using the outer primer pair SekF and Hind-DCR. The resulting PCR fragment was digested with SalI and
HindIII and cloned into SalI/HindIII-digested pLp_1261AgE6, yielding pLp_1261AgE6-DC.
To make a plasmid for overexpressing and purifying the recombinant fusion protein, the sequence
encoding AgE6 was amplified from pUC-AgE6 using the pBAD_AG_F and pBAD_AG_R primers and
inserted into BglII/HindIII-digested pBAD/HisB-EF (69) using the In-Fusion HD cloning kit (Clontech
Laboratories, Mountain View, CA), yielding the plasmid pBAD-AgE6. This expression plasmid encodes
AgE6 fused to an N-terminal His tag.
All plasmids were first transformed into E. coli TOP10 cells. Positive clones were screened by PCR and
restriction enzyme digestion, after which the PCR-amplified fragments were verified by sequencing.
Plasmids pLp_1261AgE6-DC and pLp_DC-AgE6cwa2 were purified using a PureYield plasmid miniprep
system (Promega Corp., Madison, WI) and electroporated into L. plantarum cells according to the method
of Aukrust et al. (70).
Overexpression and purification of rAgE6 protein. An overnight culture of E. coli harboring
pBAD-AgE6 was diluted to achieve an optical density at 600 nm (OD600) of 0.1 in fresh Terrific broth
medium, prepared according to the method of Tartof and Hobbs (71) and supplemented with ampicillin.
The culture was incubated at 37°C until the OD600 reached 0.6, using a Harbinger Biotechnology Lex-48
bioreactor system (Biofrontier Technology Pte Ltd., Singapore) following the manufacturer’s instructions.
Gene expression was then induced by adding arabinose (Sigma-Aldrich, St. Louis, MO) to a final
concentration of 0.2% (wt/vol). Bacterial cells were harvested after 24 h by centrifugation at 6,000  g
and 4°C for 10 min. The pellet was washed twice with phosphate-buffered saline (PBS) and stored at
20°C until purification. Inclusion bodies containing rAgE6 were recovered from bacterial cells, and the
protein was refolded according essentially to methods described previously (72, 73). Cells harvested from
a 500-ml culture were resuspended in 20 ml washing buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA,
0.1% deoxycholic acid, pH 8.0) with 20 l lysozyme (100 mg/ml), and the bacteria were sonicated for 20
min on ice using a Sonics Vibracell (30% amplitude, 5 s on/off). Insoluble material was collected by
centrifugation at 2,500  g and 4°C for 10 min and washed three times with 20 ml washing buffer.
Inclusion bodies were then solubilized in 25 to 30 ml of buffer A1 (8 M urea, 100 mM NaH2PO4, 10 mM
Tris-HCl, pH 8.0) at room temperature, and the remaining insoluble material was removed by centrifu-
gation at 12,500  g and 4°C for 15 min. Solubilized rAgE was purified using Protino Ni-NTA agarose
(Macherey-Nagel GmbH & Co. KG). The protein was washed 5 times in the column by alternating
between washing buffer 1 (3 M urea, 50 mM NaH2PO4, pH 8.0) and washing buffer 2 (3 M urea, 60%
isopropanol, 10 mM Tris-HCl, pH 8.0) before eluting with buffer B1 (8 M urea, 100 mM NaH2PO4, 10 mM
Tris-HCl, 150 mM imidazole, pH 8.0). Fractions containing rAgE were dialyzed against dialysis buffer 1 (3
M urea, 10 mM Tris-HCl, pH 8.5) using SnakeSkin dialysis tubing (10-kDa molecular mass cutoff; Thermo
Fisher Scientific, Waltham, MA, USA). Dialyzed protein was further purified by anion-exchange chroma-
tography on a HiTrap QFF 5-ml column (GE Healthcare), using the dialysis buffer as the starting buffer.
The protein was eluted by applying a linear gradient of 0 to 50% buffer B2 (3 M urea, 10 mM Tris-HCl,
1 M NaCl, pH 8.5) for 40 min at a flow rate of 3 ml/min. Fractions containing rAgE6 were pooled and
dialyzed against dialyzing buffer 2 (20 mM glycine, pH 9.2) at 4°C for 24 h. The protein concentration was
determined using the Bradford microassay (Bio-Rad Laboratories Inc., Hercules, CA).
Harvesting of recombinant L. plantarum strains. Overnight cultures of L. plantarum strains were
diluted in fresh MRS medium to an OD600 of 0.1 and incubated at 37°C until the OD600 reached 0.3.
AgE6 expression was then induced by adding the IP-673 peptide pheromone (Caslo, Lyngby, Denmark)
to a final concentration of 25 ng/ml (38). The bacterial cells were harvested 3 h after induction by
centrifugation at 5,000  g and 4°C for 5 min. Pellets were washed twice with PBS before use in
subsequent experiments. To determine the number of CFU, harvested bacterial cells were cultivated on
solid MRS medium supplemented with antibiotics for 48 h and the colonies were counted.
Crude cell-free protein extract preparation. Bacterial cells from a 50-ml culture containing 1  109
CFU/ml of L. plantarum were harvested 3 h after induction (as described above) and resuspended in 1
ml PBS. Cell-free protein extracts were prepared by disrupting cells in FastPrep tubes containing 1.5 g of
glass beads (size 106 m; Sigma-Aldrich) using a FastPrep FP120 cell disrupter with a shaking speed
of 6.5 m/s for 45 s. Cell debris was removed by centrifugation at 12,000  g and 4°C for 2 min.
Western blot analysis. To analyze AgE6 expression in L. plantarum, protein extracts (prepared as
described above) were separated by SDS-polyacrylamide gel electrophoresis using 10% Mini-Protean
TGX precast gels (Bio-Rad) and transferred to a nitrocellulose membrane using the iBlot dry-blotting
system (Invitrogen). The proteins were detected with the SNAP i.d. 2.0 protein detection system (Merck
kGaA, Darmstadt, Germany) using a specific monoclonal mouse anti-ESAT-6 antibody (Abcam, Cam-
bridge, United Kingdom) diluted 1:15,000 and subsequently a polyclonal horseradish peroxidase (HRP)-
conjugated rabbit anti-mouse IgG (Dako, Denmark A/S) diluted 1:7,500.
Dot blot analysis. To evaluate the amount of AgE6 antigen on the bacterial surface and to compare
this with the AgE6 fraction in the total protein extract, bacteria were harvested 3 h after induction and
protein extracts were prepared as described above. A cell suspension with 1  109 CFU/ml of recom-
binant L. plantarum (surface-located AgE6) and a protein extract from the same amount of cells (total
AgE6) were diluted 5-fold, after which series of 2-fold serial dilutions were prepared. A 2-l volume of
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each dilution was applied to a nitrocellulose membrane, which was then blocked with 3% (wt/vol) bovine
serum albumin (BSA; Sigma-Aldrich) in Tris-buffered saline with Tween 20 (TTBS) buffer (0.1% [vol/wt]
Tween 20, 150 mM NaCl, 10 mM Tris-HCl, pH 7.5) for 30 min at room temperature. The AgE6 proteins
were detected by incubating for 1 h with monoclonal mouse anti-ESAT-6 antibodies and then incubating
1 h with polyclonal HRP-conjugated rabbit anti-mouse IgG.
Flow cytometry and indirect immunofluorescence microscopy of L. plantarum expressing
AgE6. Bacterial cells were harvested as described above. Approximately 1  109 CFU was resuspended in 50
l PBS containing 2% BSA and 0.4 l monoclonal mouse anti-ESAT-6 antibody and then incubated for 30 min
on ice. After incubation, cells were centrifuged at 5,000  g for 5 min and washed 4 times with PBS containing
2% BSA at 4°C. Subsequently, cells were resuspended in 50 l PBS containing 2% BSA and 0.8 l polyclonal
rabbit fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibody (Sigma-Aldrich) and then incubated
on ice in the dark for 30 min. Cells were collected by centrifugation, washed 4 times with PBS, and
resuspended in 100 l PBS without BSA at 4°C. The resulting bacterial suspensions were immediately analyzed
by flow cytometry using a MACSQuant analyzer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. For indirect immunofluorescence microscopy, bacteria were
visualized under an Axio Observer.z1 microscope (Zeiss, Germany), and the fluorescence was acquired at
excitation wavelengths of 450 to 490 nm and emission wavelengths of 500 to 590 nm.
Isolation of human peripheral blood mononuclear cells. Tuberculosis-positive patients were
diagnosed using the interferon gamma release assay (IGRA) for tuberculosis (74) at Østfold Hospital Trust
(SiØ) in Kalnes, Norway. Blood was collected from TB-positive volunteers after they signed a consent form
approved by the Regional Committee for Medical and Health Research Ethics (REK). Human PBMCs were
isolated and handled according to institutional ethical guidelines (Østfold Hospital Trust, Norway). Cells
were isolated by density gradient centrifugation for 25 min at 1,500  g using Lymphoprep (Axis-Shield
Diagnostics Ltd., Dundee, Scotland) at room temperature. The PBMCs were washed four times with PBS
to remove the platelets. The cells were maintained in RPMI 1640 medium (Gibco, Thermo Fisher
Scientific) supplemented with 10% (vol/vol) fetal bovine serum (FBS; PAA Cell Culture Company, BioPath
Stores, Cambridge, United Kingdom) and 1% (vol/vol) penicillin-streptomycin (Sigma-Aldrich) in a
humidified incubator at 37°C with 5% CO2.
Human lymphocyte proliferation assay. T-cell proliferation was measured using the thymidine
incorporation assay. Briefly, 1  105 freshly isolated PBMCs were seeded in triplicate into the wells of
96-well plates. Recombinant L. plantarum cells were prepared as described above. Next, 1  107 CFU
quantities of L. plantarum strains were inactivated by UV irradiation for 45 min, washed with PBS,
resuspended in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin, and then added
to the PBMCs. As controls, PBMCs were stimulated with 50 ng/ml purified protein derivative (PPD; Statens
Serum Institut, Denmark) or 0.75  105 to 3  105 BCG bacteria (InterVax Ltd., Toronto, Canada).
Nonstimulated PBMCs were used as a negative control. The cells were incubated with stimuli for 8 to 10
days in a humidified incubator at 37°C with 5% CO2. At 24 h before harvesting, the cells were pulsed with
20 l 0.5 Ci [methyl-3H]thymidine (PerkinElmer Inc., Australia) in RPMI 1640 (supplemented with 10%
FBS and 1% penicillin-streptomycin). Cells were harvested using a Packard Filtermate 196 cell harvester
(Canberra Packard, Mt. Waverly, VIC, Australia) with glass fiber filters (PerkinElmer) and analyzed using a
TopCount NXT microplate scintillation and luminescence counter (PerkinElmer) according to the man-
ufacturers’ instructions.
Immunization protocol. All animal experiments were approved by the Norwegian Animal Research
Authority (Mattilsynet, Norway). Female 6- to 8-week-old C57BL/6 BomTac mice were purchased from
Taconic Bioscience (Ejby, Denmark) via Folkehelseinstituttet (Oslo, Norway). Mice were housed under
pathogen-free conditions in individually ventilated cages (Innovive Inc., San Diego, CA, USA) under
standard conditions (12 h light/dark cycle, 23 to 25°C, 45 to 50% relative humidity). Water and the
standard diet (RM1; SDS Special Diet Services, Whitham, United Kingdom) were given ad libitum for
the duration of the study. Mice were divided into 10 groups (n  4 each), and two administration
routes were applied: oral (5 groups) and intranasal (5 groups). All experimental groups are listed and
described in Table 3. L. plantarum cells were prepared as described above. Bacterial cultures were
harvested 3 to 6 days before each immunization, and the washed cells were stored at 20°C.
Subsamples of the harvested cells were used to determine the CFU and to carry out flow cytometry
for confirming the proper expression and surface location of the antigens. The bacterial pellets were
resuspended in PBS on the day of administration. The immunization protocol was established based
on published data (e.g., see references 75 to 78). For intranasal immunization, mice were adminis-
tered 20 l PBS (negative control) or PBS containing 1  109 CFU L. plantarum or 0.3  105 to 1.2 
TABLE 3 Experimental groups used for oral and intranasal immunization of mice
Vaccine Experimental group
PBS Negative-control group, mice immunized with PBS
Lp_Ev Negative-control group, mice immunized with L. plantarum not
expressing the AgE6 antigen
Lp_1261AgE6-DC Mice immunized with L. plantarum producing AgE6 with an N-terminal
lipoprotein anchor and DC-targeting peptide
Lp_DC-AgE6cwa2 Mice immunized with L. plantarum producing AgE6 with a C-terminal cell
wall anchor and DC-targeting peptide
BCG Control group, mice immunized with BCG
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105 BCG bacteria at days 1, 2, 12, 14, 25, and 26. For oral immunization, mice were administered 100
l PBS (negative control) or PBS containing 1  109 CFU L. plantarum or 0.3  105 to 1.2  105 BCG
bacteria at days 1, 2, 3, 13, 14, 15, 25, 26, and 27. Mice were sacrificed by cervical dislocation under
anesthesia at day 38 for intranasal immunization and at day 40 for oral immunization.
Isolation of mouse PBMCs. Blood was collected by cardiac puncture from mice anesthetized with
a mixture of zolazepam (75 mg/kg of body weight), tiletamine (75 mg/kg of body weight), and xylazine
(1.8 mg/kg of body weight). Blood was mixed with an equal volume of PBS, layered onto 3 ml of
Histopaque-1077 solution (Sigma), and centrifuged at 400  g for 30 min at room temperature.
Mononuclear cells were collected and washed 3 times with PBS by centrifuging at 250  g for 10 min
at room temperature. Cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 1%
penicillin-streptomycin, and 50 M -mercaptoethanol (Sigma-Aldrich) in a humidified incubator at 37°C
with 5% CO2. The yields of PBMCs from mice immunized intranasally were in the ranges of 4  105 to
54  105 cells/ml for PBS, 0.8  105 to 7.9  105 cells/ml for Lp_Ev, 0.5  105 to 4.8  105 cells/ml for
Lp_1261AgE6-DC, 2.2  105 to 7.1  105 cells/ml for Lp_DC-AgE6cwa2, and 1.5  105 to 5.2  105
cells/ml for BCG groups; cells were pooled within each group (4 mice per group).
Isolation of splenocytes. The spleens were collected, mashed through 100-m Corning cell strainers
(Sigma-Aldrich), and centrifuged at 300  g for 10 min at room temperature. The cell pellets were
resuspended and incubated in red cell lysis buffer (Sigma-Aldrich) for 3 min and washed two times with
RPMI 1640 medium. Cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 1%
penicillin-streptomycin, and 50 M -mercaptoethanol (Sigma-Aldrich) in a humidified incubator at 37°C
with 5% CO2.
Feces. On the day of termination, fecal samples were collected from individual mice vaccinated orally
and pooled within each group (4 mice per group). Feces were resuspended at a concentration of 100
mg/ml in PBS containing protease inhibitors (cOmplete EDTA-free protease inhibitor cocktail tablets;
Roche Diagnostics GmbH, Germany), homogenized mechanically by vortexing, and centrifuged at
10,000  g for 10 min at 4°C. Supernatants were aliquoted and stored at 20°C until analysis.
IFN- secretion by splenocytes. The frequency of IFN--producing cells was determined by ELISPOT
assay according to the supplier’s instructions (Mabtech AB, Nacka Strand, Sweden). Briefly, 2.5  105 cells
were stimulated with 10 g/ml of purified rAgE6 in duplicate for 36 to 48 h. The frequency of
cytokine-secreting cells was measured using the CTL-ImmunoSpot S6 microanalyzer (CTL-Europe GmbH,
Bonn, Germany) according to the manufacturer’s instructions. Unstimulated lymphocytes were used as
a negative control.
Mouse lymphocyte proliferation assay. The proliferation of PBMCs purified from mice immunized
via the intranasal route was measured by the thymidine incorporation assay as described above. Briefly,
1  105 freshly isolated cells were seeded in the wells of 96-well plates. The cells were stimulated with
10 g/ml rAgE6 in triplicates. The PBMCs were incubated with stimuli for 7 days in a humidified incubator
at 37°C with 5% CO2. Unstimulated lymphocytes were used as a negative control.
IgA antibody assay. IgA antibodies in fecal samples were determined by enzyme-linked immu-
nosorbent assay (ELISA). Microtiter plates were coated with 10 g/ml rAgE6 for antigen-specific IgA and
with 1 g/ml goat anti-mouse IgA (Sigma) for total IgA detection and incubated overnight at room
temperature. Supernatants from the fecal samples were diluted 1.5-fold for AgE6-specific IgA and 1:100
for total IgA in PBS containing 0.1% Tween 20 (Sigma-Aldrich) and 0.1% (wt/vol) BSA and then incubated
in the precoated microtiter plate overnight at 4°C (100 l per well). HRP-conjugated goat anti-mouse IgA
(Sigma) was used for color development. The OD at 405 nm, with the reference wavelength set to 650
nm, was measured using a Sunrise plate reader (Tecan Group Ltd., Männedorf, Switzerland).
Statistical tests. Statistical significance was determined by one-way analyses of variance (ANOVAs)
with Tukey’s post hoc tests using GraphPad Prism (GraphPad Software, San Diego, CA). Results are
presented as means  the standard errors of the means (SEM).
ACKNOWLEDGMENTS
We thank Øystein Almås and Åse-Berit Mathisen at the Østfold Hospital Trust (SiØ)
in Kalnes, Norway, for cooperating and providing blood from TB-positive patients, Inger
Øynebråten at OUH for help with ELISPOT assays, Claus Aagaard and Frank Follman at
SSI for technical discussions related to the purification of the antigen, and Ewa Piskorz
for technical assistance during animal experiments.
This work was funded by a Ph.D. fellowship from the Norwegian University of Life
Sciences to Katarzyna Kuczkowska and by grants 196363 and 234502 from the Globvac
program of the Research Council of Norway.
REFERENCES
1. Lerm M, Netea MG. 2016. Trained immunity: a new avenue for tubercu-
losis vaccine development. J Intern Med 279:337–346. https://doi.org/
10.1111/joim.12449.
2. WHO. 2015. Global tuberculosis report. World Health Organization, Ge-
neva, Switzerland.
3. Kaufmann SH. 2010. Novel tuberculosis vaccination strategies based on
understanding the immune response. J Intern Med 267:337–353. https://
doi.org/10.1111/j.1365-2796.2010.02216.x.
4. da Costa C, Walker B, Bonavia A. 2015. Tuberculosis vaccines—state of
the art, and novel approaches to vaccine development. Int J Infect Dis
32:5–12. https://doi.org/10.1016/j.ijid.2014.11.026.
5. Parida SK, Kaufmann SH. 2010. Novel tuberculosis vaccines on the
Display of M. tuberculosis Antigens on Lactobacillus Applied and Environmental Microbiology
January 2017 Volume 83 Issue 2 e02782-16 aem.asm.org 13
 on F








horizon. Curr Opin Immunol 22:374 –384. https://doi.org/10.1016/j
.coi.2010.04.006.
6. Brennan MJ, Thole J. 2012. Tuberculosis vaccines: a strategic blueprint
for the next decade. Tuberculosis 92:S6 –S13. https://doi.org/10.1016/
S1472-9792.
7. Armitige LY, Jagannath C, Wanger AR, Norris SJ. 2000. Disruption of the
genes encoding antigen 85A and antigen 85B of Mycobacterium tuber-
culosis H37Rv: effect on growth in culture and in macrophages. Infect
Immun 68:767–778. https://doi.org/10.1128/IAI.68.2.767-778.2000.
8. Denis O, Lozes E, Huygen K. 1997. Induction of cytotoxic T-cell responses
against culture filtrate antigens in Mycobacterium bovis bacillus
Calmette-Guérin-infected mice. Infect Immun 65:676 – 684.
9. Dietrich J, Weldingh K, Andersen P. 2006. Prospects for a novel vaccine
against tuberculosis. Vet Microbiol 112:163–169. https://doi.org/
10.1016/j.vetmic.2005.11.030.
10. Okkels LM, Andersen P. 2004. Protein-protein interactions of proteins
from the ESAT-6 family of Mycobacterium tuberculosis. J Bacteriol 186:
2487–2491. https://doi.org/10.1128/JB.186.8.2487-2491.2004.
11. Mahmood A, Srivastava S, Tripathi S, Ansari MA, Owais M, Arora A. 2011.
Molecular characterization of secretory proteins Rv3619c and Rv3620c
from Mycobacterium tuberculosis H37Rv. FEBS J 278:341–353. https://
doi.org/10.1111/j.1742-4658.2010.07958.x.
12. Agger EM. Novel adjuvant formulations for delivery of anti-tuberculosis
vaccine candidates. Adv Drug Deliv Rev 102:73– 82. https://doi.org/10
.1016/j.addr.2015.11.012.
13. Andersen P, Urdahl KB. 2015. TB vaccines; promoting rapid and durable
protection in the lung. Curr Opin Immunol 35:55– 62. https://doi.org/
10.1016/j.coi.2015.06.001.
14. Ernst JD. 2012. The immunological life cycle of tuberculosis. Nat Rev
Immunol 12:581–591. https://doi.org/10.1038/nri3259.
15. Ottenhoff THM, Kaufmann SHE. 2012. Vaccines against tuberculosis:
where are we and where do we need to go? PLoS Pathog 8:e1002607.
https://doi.org/10.1371/journal.ppat.1002607.
16. Medina E, Guzmán CA. 2001. Use of live bacterial vaccine vectors for
antigen delivery: potential and limitations. Vaccine 19:1573–1580.
https://doi.org/10.1016/S0264-410X(00)00354-6.
17. Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM. 2013. Pre-existing
immunity against vaccine vectors–friend or foe? Microbiology 159:1–11.
https://doi.org/10.1099/mic.0.049601-0.
18. Griffiths KL, Khader SA. 2014. Novel vaccine approaches for protection
against intracellular pathogens. Curr Opin Immunol 28:58 – 63. https://
doi.org/10.1016/j.coi.2014.02.003.
19. LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A,
Vergnolle N, Langella P, Azevedo V, Chatel JM, Miyoshi A, Bermudez-
Humaran LG. 2013. Mucosal targeting of therapeutic molecules using
genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett
344:1–9. https://doi.org/10.1111/1574-6968.12159.
20. Michon C, Langella P, Eijsink VGH, Mathiesen G, Chatel JM. 2016. Display
of recombinant proteins at the surface of lactic acid bacteria: strategies
and applications. Microb Cell Fact 15:70. https://doi.org/10.1186/s12934
-016-0468-9.
21. Juárez-Rodríguez MD, Yang J, Kader R, Alamuri P, Curtiss R, III, Clark-
Curtiss JE. 2012. Live attenuated Salmonella vaccines displaying regu-
lated delayed lysis and delayed antigen synthesis to confer protection
against Mycobacterium tuberculosis. Infect Immun 80:815– 831. https://
doi.org/10.1128/IAI.05526-11.
22. Parida SK, Huygen K, Ryffel B, Chakraborty T. 2005. Novel bacterial
delivery system with attenuated Salmonella typhimurium carrying plas-
mid encoding Mtb antigen 85A for mucosal immunization: establish-
ment of proof of principle in TB mouse model. Ann N Y Acad Sci
1056:366 –378. https://doi.org/10.1196/annals.1352.030.
23. Daifalla N, Cayabyab MJ, Xie E, Kim HB, Tzipori S, Stashenko P, Duncan
M, Campos-Neto A. 2015. Commensal Streptococcus mitis is a unique
vector for oral mucosal vaccination. Microbes Infect 17:237–242. https://
doi.org/10.1016/j.micinf.2014.11.002.
24. Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and pro-
phylactic molecules using lactic acid bacteria. Nat Rev Microbiol
6:349 –362. https://doi.org/10.1038/nrmicro1840.
25. Bermúdez-Humarán LG, Kharrat P, Chatel J-M, Langella P. 2011. Lacto-
cocci and lactobacilli as mucosal delivery vectors for therapeutic pro-
teins and DNA vaccines. Microb Cell Fact 10:S4. https://doi.org/10.1186/
1475-2859-10-S1-S4.
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